Table 2: ADAR1, N4BP1, PSME1 Expression in PBMCs for Hepatitis B Treatment Response

A prospective study of HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α for 48 weeks. The dataset likely contains mRNA expression levels of ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells (PBMCs), correlated with virological and serological response outcomes. The data was authored by Hao Pang and shared on figshare under a CC-BY-4.0 license.

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Assessing the likelihood of HBsAg clearance (serological response) using gene expression data from PBMCs.
• Evaluating the diagnostic performance of candidate biomarkers by calculating area under the curve (AUC) metrics.
• Conducting multivariate analysis to identify factors independently associated with therapeutic response.

Strengths

• Includes specific performance metrics: AUC values for ADAR1, N4BP1, and PSME1 predictions range from 0.7198 to 0.9230.
• Defined patient cohorts: 47.25% virological response rate and 35.16% serological response rate after 48 weeks.
• Prospective study design with follow-up at specific time points (weeks 12, 24, 48).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (16.8 KB), indicating limited scope, likely a single summary table.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Real-time quantitative PCR detection of mRNA levels in PBMCs from a clinical trial cohort.

Time Range

Treatment and follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:08; freshness should be verified.

Geography

null